Overexpression of fibroblast growth factor receptor 1 (FGFR1), found in ≤8% of hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) breast cancer cases, is correlated with decreased overall survival and resistance to endocrine therapy (ET). The gene discussed is ERBB2; the disease is breast cancer.